Galapagos appoints Piet Wigerinck as Senior VP Development


Galapagos NV announced the appointment of Dr. Piet Wigerinck as Senior Vice President of Development. As a member of Galapagos' Executive Team, Dr. Wigerinck will oversee the development of Galapagos' drug candidates, including pre-clinical development, chemistry manufacturing & control (CM&C), regulatory aspects, and clinical development.

Dr. Piet Wigerinck joins Galapagos from Tibotec in Belgium (a subsidiary of Johnson & Johnson) where he was VP Drug Discovery, Early Development and CM&C, and a member of the Management Board. He started his professional career as a medicinal chemist at Janssen Research Foundation in 1992. He then joined Tibotec in 1998, where, under his leadership, TMC114 (PrezistaTM) was selected and moved forward into clinical trials. Dr. Wigerinck also played a key role in Tibotec's expansion into novel diseases such as Hepatitis C and advanced several compounds into Phase I and Phase II clinical trials. He brings over 15 years of research and development experience from both big pharma and biotech to Galapagos. Piet Wigerinck holds a PhD from the K.U. Leuven and is inventor on more than 25 patent applications.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances